Balancing motivation through VTA GABA/Glutamate co-transmission
Balancing motivation through VTA GABA/Glutamate co-transmission
批准号:
10506783
负责人:
Shelley May Warlow
金额:
$12.06万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-01 至 2024-08-31
关键词:
AffectAmericanAmygdaloid structureAnxiety DisordersAutomobile DrivingAxonBehaviorBehavior ControlBehavioralBehavioral AssayBiological AssayBipolar DepressionBipolar DisorderBrainCRISPR/Cas technologyCalciumCalcium SignalingCellsCharacteristicsChronicComplexCompulsive BehaviorDevelopmentDiseaseDopamineEquilibriumExposure toFiberGenesGlutamatesHabenulaHyperactivityIncentivesLateralLeadMajor Depressive DisorderManicMeasuresMediatingMembrane PotentialsMental DepressionModelingMonitorMood DisordersMoodsMotivationMusNegative ReinforcementsNeuronsNeurotransmittersPhasePhotometryPhysiologicalPhysiologyPopulationPopulation HeterogeneityPositive ReinforcementsPsychological reinforcementResearchResearch PersonnelRewardsRoleShapesSignal TransductionSomatostatinStressStructureSucroseTestingTherapeutic EffectTrainingVentral Tegmental Areabasecell typedefined contributiondepressive symptomsdesigner receptors exclusively activated by designer drugsdopaminergic neuronexperienceexperimental studyfaculty mentorgamma-Aminobutyric Acidin vivoin vivo calcium imaginginsightmotivated behaviorneural circuitneuropsychiatric disordernew therapeutic targetnoveloptogeneticspatch clamppostsynapticpreventprogramsprotein kinase C-deltareduce symptomsresponsereward circuitryskillstherapeutically effectivetooltransmission process
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Identifying the neural circuit mechanisms underlying both homeostatic and uncontrolled motivation are
crucial for developing more targeted and effective therapeutic treatments for neuropsychiatric disorders like
major depression or bipolar disorder. Within mesolimbic brain reward circuitry, the ventral tegmental area
(VTA) is a major regulator of both reward and aversion. While generally reduced to its dopamine projection
neurons, the VTA also contains neurons that co-release inhibitory GABA and excitatory glutamate and, similar
to dopamine projections, can modulate motivation. However, the functional role of this GABA/glutamate co-
release is still not well understood, and major questions regarding their role in positive vs. negative
reinforcement remain. In particular, why would neurons simultaneously send an inhibitory and excitatory
signal? This set of proposed experiments will systematically test the hypothesis that VTA GABA/glutamate co-
release serves as a mechanism to balance postsynaptic activity and motivation in a homeostatic manner.
Using optogenetics to drive VTA GABA/glutamate co-release in downstream structures that regulate mood and
motivation, I will apply gene-editing tools (CRISPR/Cas9) to test the selective contribution of GABA vs.
glutamate release in behavioral reinforcement (Aim 1). I will then apply chemogenetic approaches and chronic
behavioral manipulations that alter postsynaptic activity to test the net in vivo effect of optogenetically driving
VTA GABA/glutamate co-release using in vivo calcium imaging (Aim 2). These experiments will reveal basic
mechanisms of neurotransmitter co-release and uncover their role within mesolimbic circuitry in balancing
motivation and preventing prolonged excitation/inhibition of efferent structures associated with extreme
motivational states. The capability of GABA/glutamate co-release to normalize activity can provide a novel
target for treating disorders of imbalanced motivation such as bipolar disorder or depression. A strong
interdisciplinary team of faculty mentors and experts will provide the scientific training required for these
proposed experiments (gene-editing and fiber photometry) as well as professional development training to
facilitate a successful transition to the R00 phase of this proposal. During the R00 phase, I will unify my prior
expertise with newly acquired skills to determine the physiological and behavioral role of a newly-described
VTA GABA/glutamate projection to amygdala. Using in vivo calcium imaging, I will first monitor activity of VTA
GABA/glutamate terminals in amygdala during an effort-based instrumental sucrose task, and will then identify
the net effect of optogenetically stimulating VTA GABA/glutamate terminals on cell-defined amygdala
populations (Aim 3). These results will significantly expand our understanding of the role of VTA co-release in
complex motivated behavior relevant to models of bipolar disorder and depression, and will crucially pave the
way for more targeted approaches that form the basis my independent research program.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Balancing motivation through VTA GABA/Glutamate co-transmission
-
批准号:10671522
-
项目类别:
-
资助金额:$12.06万
-
财政年份:2022
-
负责人:Shelley May Warlow
-
依托单位:
Balancing motivation through VTA GABA/Glutamate co-transmission
-
批准号:10759702
-
项目类别:
-
资助金额:$5.39万
-
财政年份:2022
-
负责人:Shelley May Warlow
-
依托单位:
The role of VTA neurotransmitter co-release in health and disease
-
批准号:10318170
-
项目类别:
-
资助金额:$5.05万
-
财政年份:2020
-
负责人:Shelley May Warlow
-
依托单位:
The role of VTA neurotransmitter co-release in health and disease
-
批准号:10078844
-
项目类别:
-
资助金额:$6.64万
-
财政年份:2020
-
负责人:Shelley May Warlow
-
依托单位:
The role of VTA neurotransmitter co-release in health and disease
-
批准号:9911238
-
项目类别:
-
资助金额:$6.12万
-
财政年份:2020
-
负责人:Shelley May Warlow
-
依托单位:
海外基金